Physician profile
Deborah A Smith
NPI 1225156821
$1,641.48
in general payments reported to CMS, 2019-2025
29 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Oncology (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $831 · 2022: $150 · 2023: $151 · 2024: $236 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573 · Education: $87.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.66 |
| Education | $87.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $193.92 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $187.02 | 2021-2025 | Lynparza, Enhertu |
| Incyte Corporation | $159.99 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $99.95 | 2021 | |
| Glaxosmithkline, LLC. | $92.27 | 2021-2025 | Blenrep, Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $74.49 | 2021-2025 | Opdivo |
| Karyopharm Therapeutics INC. | $72.99 | 2021-2022 | |
| Janssen Biotech, INC. | $71.68 | 2021-2025 | Erleada, Talvey, Darzalex |
| Regeneron Healthcare Solutions, INC. | $71.18 | 2021-2024 | Libtayo |
| Astellas Pharma US INC | $70.89 | 2022-2024 | Xtandi |
| Mirati Therapeutics, INC. | $69.60 | 2023-2024 | Krazati |
| Abbvie INC. | $58.57 | 2021-2025 | |
| Amag Pharmaceuticals, INC. | $41.40 | 2021 | |
| Boston Scientific Corporation | $38.93 | 2021-2022 | |
| Legend Biotech USA INC. | $37.58 | 2025 | Carvykti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $36.14 | 2021-2022 | |
| Beigene USA, INC. | $33.46 | 2022-2023 | Brukinsa |
| Merck Sharp & Dohme LLC | $29.89 | 2021-2025 | Keytruda, Lynparza |
| Myriad Genetic Laboratories, INC. | $28.97 | 2021 | |
| Eisai INC. | $21.95 | 2025 | |
| Blueprint Medicines Corporation | $20.48 | 2025 | Ayvakit |
| Beone Medicines USA, INC. | $19.94 | 2025 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $19.92 | 2023 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $17.85 | 2021 | |
| Pharmaessentia USA Corporation | $16.98 | 2024 | Besremi |
| Pfizer INC. | $15.60 | 2024 | |
| Seagen INC. | $14.50 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.03 | 2021 | |
| Kite Pharma, INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.